In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
health.wusf.usf.edu26m
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
New schizophrenia drug could 'change the lives of millions of people'
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
precisionmedicineonline1h
FDA Panel Finds Limited Immunotherapy Benefit in PD-L1-Negative Gastric, Esophageal Cancer
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
New Drug For Schizophrenics Has Experts Excited
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.
MM&M3h
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
mashviral4h
New Schizophrenia Drug Gets FDA Green Light — First of Its Kind in Over 30 years
The U. S. Food and Drug Administration (FDA) has signed off on Cobenfy, the first revolutionary treatment for schizophrenia ...
Top Stock Movers Now: Wynn Resorts, AT&T, Newmont, and More
U.S. equities were mixed at midday as the Federal Reserve's favored measure of inflation was lower than anticipated.
btimesonline5h
FDA Approves Bristol Myers Squibb’s Cobenfy, First Novel Schizophrenia Drug in 70 Years
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
SchaeffersResearch.com5h
Pharma Stock Rises on Cleared Schizophrenia Treatment
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma ...
The American Journal of Managed Care5h
First Schizophrenia Treatment Approved in Decades Targets Cholinergic Receptors
Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...